An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
NCT06443944 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-04-14
Summary
This is an open-label, expanded access trial designed to provide access to cretostimogene in patients with NMIBC (specifically CIS with or without HG Ta/T1) unresponsive to BCG.
Conditions
- Non-Muscle Invasive Bladder Cancer
- Urothelial Carcinoma
- Urologic Cancer
- Bladder Cancer
Interventions
- DRUG
-
Cretostimogene Grenadenorepvec
Engineered Oncolytic Adenovirus
- OTHER
-
n-dodecyl-B-D-maltoside
Transduction-enhancing agent
Sponsors & Collaborators
-
CG Oncology, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
NCT04149574 ·Status: TERMINATED ·Phase: PHASE3
-
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
NCT07000084 ·Status: RECRUITING ·Phase: PHASE3
-
Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)
NCT06350838 ·Status: COMPLETED ·Phase: PHASE1
-
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
NCT06441110 ·Status: RECRUITING ·Phase: PHASE3
-
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NCT06800963 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
NCT02138734 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.
NCT07064863 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC
NCT05768347 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073 ·Status: RECRUITING ·Phase: PHASE2
-
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer
NCT02311101 ·Status: COMPLETED ·Phase: PHASE1
-
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
NCT06810141 ·Status: AVAILABLE
-
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study
NCT06990061 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
BCG for Therapeutic Use Phase I Clinical Trial
NCT06100653 ·Status: COMPLETED ·Phase: PHASE1
-
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer
NCT00880854 ·Status: WITHDRAWN ·Phase: PHASE1
-
BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer
NCT06462001 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
NCT06241755 ·Status: RECRUITING ·Phase: PHASE3
-
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
NCT05943106 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC
NCT01284205 ·Status: WITHDRAWN ·Phase: PHASE3
-
Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer
NCT02143804 ·Status: WITHDRAWN ·Phase: PHASE2
-
Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
NCT00109655 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
NCT03519256 ·Status: TERMINATED ·Phase: PHASE2
-
Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer
NCT02948543 ·Status: UNKNOWN ·Phase: PHASE3
-
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06545955 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
NCT01438112 ·Status: TERMINATED ·Phase: PHASE2/PHASE3